Collegium Pharmaceutical, Inc. (COLL)

Market Cap	876.23M
Revenue (ttm)	664.28M
Net Income (ttm)	43.89M
Shares Out	32.13M
EPS (ttm)	1.25
PE Ratio	21.78
Forward PE	3.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	469,639
Open	26.92
Previous Close	27.05
Day's Range	26.92 - 27.90
52-Week Range	23.23 - 42.29
Beta	0.63
Analysts	Strong Buy
Price Target	43.60 (+59.88%)
Earnings Date	May 8, 2025

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Financial Performance

In 2024, Collegium Pharmaceutical's revenue was $631.45 million, an increase of 11.41% compared to the previous year's $566.77 million. Earnings were $69.19 million, an increase of 43.68%.

Analyst Forecast

According to 5 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price forecast is $43.6, which is an increase of 59.88% from the latest price.

Price Target

$43.6

(59.88% upside)

Analyst Consensus: Strong Buy